Share on LinkedInShare on LinkedIn

ARTICLE · 13 NOVEMBER 2026

Mayne v Cosette MAC Decision Upheld On Appeal

Herbert Smith Freehills Kramer LLP
Herbert Smith Freehills Kramer LLP
Contributor
Herbert Smith Freehills Kramer LLP

Herbert Smith Freehills Kramer LLP

We have one of the largest Southeast Asia international law practices, working across the region...

View firm profile
Explore more from Herbert Smith Freehills Kramer LLP

The NSW Court of Appeal has upheld a lower court decision in a high-stakes dispute between Cosette Pharmaceuticals and Mayne Pharma Group, clarifying critical principles around Material Adverse Change clauses in M&A transactions. The ruling addresses when parties can legitimately terminate acquisition agreements and how courts interpret financial thresholds in scheme implementation deeds.

AustraliaCorporate/Commercial Law

The NSW Court of Appeal has rejected all grounds of appeal brought by Cosette Pharmaceuticals, Inc in its attempt to establish it had a right to terminate the scheme implementation deed with Mayne Pharma Group Limited, reinforcing that the threshold for proving a MAC involves a high standard.

In brief

The NSW Court of Appeal has rejected all grounds of appeal brought by Cosette Pharmaceuticals, Inc (Cosette) in its attempt to establish it had a right to terminate the scheme implementation deed with Mayne Pharma Group Limited (Mayne).

The Court of Appeal’s decision makes clear that:

  • The terms of the SID are the source of truth and Courts will interpret the drafting strictly, and accordingly parties should be very specific in MAC drafting.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from